Sale

HIV Drugs Market

HIV Drugs Market Size, Share, Trends, Analysis, Report: By Medication Class: Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Others; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032

HIV Drugs Market Outlook

The HIV drug market size attained a value of USD 33.54 billion in 2023. The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2024-2032 to attain a value of USD 49.85 billion by 2032.

 

HIV Drugs Market By Distribution Channel

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

HIV Drugs Market Overview

Human immunodeficiency virus (HIV) is a life-threatening condition that can be transferred from one person to another through blood and/or sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease has positively impacted the demand for HIV drugs. According to the estimates by the World Health Organization (WHO), 39 million people are living with HIV. Approximately 0.7% of adults aged between 15-49 years are living with this condition worldwide. The growing population density of HIV-infected people has been instrumental in the development and introduction of HIV drugs.

 

The HIV drugs market growth is influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of the condition. At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aid in increasing the number of CD4+ cells and decreasing the amount of virus in the blood. The introduction of generic drug acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs. The market is experiencing increased advancement in the treatment technologies by the market players. Such advancements are significantly expected to drive the market growth.

 

Expedited Drug Development to Boost HIV Drugs Market Share

In October 2023, Gilead Sciences, Inc. revealed that Sunlenca® (lenacapavir),  their latest drug was well supported to treat multi-drug resistant (MDR) HIV in adults. Administered twice a year, Sunlenca is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, used in combination with other antiretrovirals. The drug is expected to be made available in oral as well as injectable mode of administration along with multiple dosage forms. The increasing advancements to bring customization and offer precise treatment to patients is poised to drive the market for HIV drugs in the forecast period.

 

Surge in Clinical Trials to Meet the Rising HIV Drugs Market Demand

The market growth is poised to be driven by the rising number of clinical trials and continued efforts by researchers to discover an effective treatment novel therapy to treat HIV. For instance, in April 2023, UC Davis Health researchers deployed CAR T cell therapy to treat patients suffering from HIV . Leveraging immunotherapy, the first patient was dosed with anti-HIV duoCAR T cells to stimulate the immune system and treat the condition. The clinical trial was designed for 9 candidates, divided in 3 cohorts wherein patients from each cohort underwent different treatment combinations. This is indicative of rising application of advanced and alternative therapies to treat the fatal disease.

 

Global HIV Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

HIV Drugs Market Segmentation

Market Breakup by Medication Class

  • Multi-Class Combination Drugs
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Protease Inhibitors (Pls)
  • Entry Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Others

 

Market Breakup by Distribution Channel

  • Hospitals Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Pharmacies

 

Market Breakup by End User

  • Hospitals
  • Clinics
  • Others

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • China

 

HIV Drugs Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

HIV Drugs Market Regional Analysis

Geographically, North America is expected to lead the market share in the forecast period. The regional growth can be attributed to a well-established healthcare system, and the growing adoption of advanced treatment options for the HIV-infected population. The HIV drugs market size is significantly impacted by the increased number of research and development initiatives for new drug launches.

 

In September 2023, researchers at Johns Hopkins found a new injectable solution that could help manage HIV, unlike any currently available methods in the market. This new solution self-assembles into a gel under the right conditions. It releases a steady dose of the anti-HIV drug lamivudine over six weeks. The major issue that patients face while following an HIV treatment regimen is the daily management of the doses. However, this new gel treatment is poised to help people living with HIV to have a new therapy that doesn't require a daily pill regimen to prevent AIDS, making it less stressful and easy to follow.

 

The Asia Pacific region is also poised to experience significant HIV drugs market growth, owing to increasing infrastructure improvements and emphasis on spreading awareness about the condition amongst marginalised communities.

 

HIV Drugs Market: Competitor Landscape

In February 2022, ViiV Healthcare , the global specialist HIV company, announced the US Food and Drug Administration (FDA) approval for Cabenuva (cabotegravir, rilpivirine) for every two months dosing for the treatment of HIV-1 in virologically suppressed adults. The drug constitutes an extended-release injectable suspension in a single vial dose, making it suitable for easy administration. The approval was based on the positive results from ATLAS-2M phase IIIb trial.

 

The key features of the HIV drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • ViiV Healthcare Group of Companies
  • Gilead Sciences, Inc.
  • GSK Plc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • Genentech, Inc.
  • Mylan N.V.
  • CytoDyn Inc.
  • Daichii Sankyo Company, Limited
  • Pfizer Inc.
  • Shantou Huatai Pharmaceutical Co., Ltd.
  • Shengzhen Chongway Biotechnology Co., Ltd

 

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Medication Class
  • Distribution Channel
  • End User
  • Region
Breakup by Medication Class
  • Multi-Class Combination Drugs
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Protease Inhibitors (PIs)
  • Entry Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Drugs stores and retail pharmacies
  • Online pharmacie
Breakup by End User
  • Hospitals 
  • Clinics
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • China
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • ViiV Healthcare Group of Companies 
  • Gilead Sciences, Inc.
  • GSK Plc. 
  •  Merck & Co., Inc. 
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Boehringer Ingelheim International GmbH 
  • AbbVie Inc. 
  • Genentech, Inc.
  • Mylan N.V. 
  • CytoDyn Inc.
  • Pfizer Inc.
  • Daichii Sankyo Company, Limited
  • Shantou Huatai Pharmaceutical Co., Ltd.
  • Shengzhen Chongway Biotechnology Co., Ltd

 

HIV Drugs Market Report Snapshots

HIV Drugs Market Size

HIV Drugs Market Analysis

HIV Drugs Companies

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    HIV Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    HIV Epidemiology Analysis – 8 Major Markets
    5.1    8MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States HIV Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom HIV Epidemiology Forecast (2017-2032)
        5.3.1    Germany HIV Epidemiology Forecast (2017-2032)
        5.3.2    France HIV Epidemiology Forecast (2017-2032)
        5.3.3    Italy HIV Epidemiology Forecast (2017-2032)
        5.3.4    Spain HIV Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom HIV Epidemiology Forecast (2017-2032)
    5.4    Japan HIV Epidemiology Forecast (2017-2032)
6    HIV Drugs Market Overview – 8 Major Markets 
    6.1    HIV Drugs Market Historical Value (2017-2023) 
    6.2    HIV Drugs Market Forecast Value (2024-2032)
7    HIV Drugs Market Landscape – 8 Major Markets 
    7.1    HIV Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    HIV Drugs: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Medication Class
8    HIV Drugs Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    HIV Drugs Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    HIV Drugs Market Segmentation-8 Major Markets 
    11.1    HIV Drugs Market by Medication Class
        11.1.1    Market Overview
        11.1.2    Multi-Class Combination Drugs
        11.1.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        11.1.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        11.1.5     Protease Inhibitors (PIs)
        11.1.6    Entry Inhibitors
        11.1.7    HIV Integrase Strand Transfer Inhibitors
        11.1.8    Others
    11.2    HIV Drugs Market by Distribution Channel
        11.2.1    Market Overview
        11.2.2    Hospital Pharmacies
        11.2.3    Drugs stores and retail pharmacies
        11.2.4    Online pharmacies
    11.3    HIV Drugs Market by End User
        11.3.1    Market Overview
        11.3.2    Hospitals 
        11.3.3    Clinics
        11.3.4    Others
    11.4    HIV Drugs Market by Region
        11.4.1    Market Overview
        11.4.2    United States
        11.4.3    EU-4 and the United Kingdom
            11.4.3.1    Germany
            11.4.3.2    France
            11.4.3.3    Italy
            11.4.3.4    Spain
            11.4.3.5    United Kingdom
        11.4.4    Japan
        11.4.5    China
12    United States HIV Drugs Market
    12.1    HIV Drugs Market Historical Value (2017-2023) 
    12.2    HIV Drugs Market Forecast Value (2024-2032)
    12.3    United States HIV Drugs Market by Medication Class
        12.3.1    Market Overview
        12.3.2    Multi-Class Combination Drugs
        12.3.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        12.3.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        12.3.5     Protease Inhibitors (PIs)
        12.3.6    Entry Inhibitors
        12.3.7    HIV Integrase Strand Transfer Inhibitors
        12.3.8    Others
    12.4    United States HIV Drugs Market by Distribution Channel
        12.4.1    Market Overview
        12.4.2    Hospital Pharmacies
        12.4.3    Drugs stores and retail pharmacies
        12.4.4    Online pharmacies 
13    EU-4 and United Kingdom HIV Drugs Market
    13.1    EU-4 and United Kingdom HIV Drugs Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom HIV Drugs Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom HIV Drugs Market Overview
    13.4    EU-4 and United Kingdom HIV Drugs Market by Medication Class
        13.4.1    Market Overview
        13.4.2    Multi-Class Combination Drugs
        13.4.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        13.4.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        13.4.5     Protease Inhibitors (PIs)
        13.4.6    Entry Inhibitors
        13.4.7    HIV Integrase Strand Transfer Inhibitors
        13.4.8    Others
    13.5    EU-4 and United Kingdom HIV Drugs Market by Distribution Channel
        13.5.1    Market Overview
        13.5.2    Hospital Pharmacies
        13.5.3    Drugs stores and retail pharmacies
        13.5.4    Online pharmacies 
14    Japan HIV Drugs Market
    14.1    Japan HIV Drugs Market Historical Value (2017-2023) 
    14.2    Japan HIV Drugs Market Forecast Value (2024-2032)
    14.3    Japan HIV Drugs Market by Medication Class
        14.3.1    Market Overview
        14.3.2    Multi-Class Combination Drugs
        14.3.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        14.3.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        14.3.5     Protease Inhibitors (PIs)
        14.3.6    Entry Inhibitors
        14.3.7    HIV Integrase Strand Transfer Inhibitors
        14.3.8    Others
    14.4    Japan HIV Drugs Market by Distribution Channel
        14.4.1    Market Overview
        14.4.2    Hospital Pharmacies
        14.4.3    Drugs stores and retail pharmacies
        14.4.4    Online pharmacies 
15    China HIV Drugs Market
    15.1    China HIV Drugs Market Historical Value (2017-2023) 
    15.2    China HIV Drugs Market Forecast Value (2024-2032)
    15.3    China HIV Drugs Market by Medication Class
        15.3.1    Market Overview
        15.3.2    Multi-Class Combination Drugs
        15.3.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        15.3.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        15.3.5     Protease Inhibitors (PIs)
        15.3.6    Entry Inhibitors
        15.3.7    HIV Integrase Strand Transfer Inhibitors
        15.3.8    Others
    15.4    China HIV Drugs Market by Distribution Channel
        15.4.1    Market Overview
        15.4.2    Hospital Pharmacies
        15.4.3    Drugs stores and retail pharmacies
        15.4.4    Online pharmacies 
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    ViiV Healthcare Group of Companies 
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisitions
        22.1.5    Certifications
    22.2    Gilead Sciences, Inc.  
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    GSK Plc. 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Merck & Co., Inc. 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    Bristol-Myers Squibb Company 
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Johnson & Johnson Services, Inc. 
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Boehringer Ingelheim International GmbH 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    AbbVie Inc. 
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Genentech, Inc. 
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Mylan N.V. 
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    CytoDyn Inc. 
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications
    22.12    Daichii Sankyo Company, Limited 
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisitions
        22.12.5    Certifications
    22.13    Pfizer Inc.  
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisitions
        22.13.5    Certifications
    22.14    Shantou Huatai Pharmaceutical Co., Ltd. 
        22.14.1    Financial Analysis
        22.14.2    Product Portfolio
        22.14.3    Demographic Reach and Achievements
        22.14.4    Mergers and Acquisitions
        22.14.5    Certifications
    22.15    Shengzhen Chongway Biotechnology Co., Ltd
        22.15.1    Financial Analysis
        22.15.2    Product Portfolio
        22.15.3    Demographic Reach and Achievements
        22.15.4    Mergers and Acquisitions
        22.15.5    Certifications
List not exhaustive
23    HIV Drugs - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)

    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.


* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

    

Key Questions Answered in the Report

The market attained a value of about USD 33.54 billion in 2023 driven by increasing awareness of HIV across the major markets.

The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2024-2032 and is likely to reach a market value of USD 49.85 billion by 2032.

Factors such as the rising incidence of HIV among people, government initiatives, increasing available treatments in the market, and new developments by market players are major factors aiding market demand.

The surge in FDA approvals to provide effective solutions to the patients is a major market trend. In October 2023, Gilead Sciences, Inc. revealed that Sunlenca® (lenacapavir), their latest drug was well supported to treat multi-drug resistant (MDR) HIV in adults

Drug classes for HIV drugs include multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pls), entry inhibitors, and HIV integrase strand transfer inhibitors, among others.

Distribution channels include hospitals pharmacies, drug stores, retail pharmacies, and online pharmacies, among others.

End users in the market include hospitals, and clinics, among others.

The major markets include the United States, EU-4, the United Kingdom, Japan, and China.

Key players involved in the market are Gilead Sciences, Inc., GSK Plc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Genentech, Inc., Mylan N.V., CytoDyn Inc., Daichii Sankyo Company, Limited, Pfizer Inc., Shantou Huatai Pharmaceutical Co., Ltd., Shengzhen Chongway Biotechnology Co., Ltd, and ViiV Healthcare Group of Companies.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER